2OK Stock Chart & Stats
€0.01
€0.03(15.76%)
At close: 4:00 PM EST
€0.01
€0.03(15.76%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)2.59K
Market Cap
€5.11M
Enterprise Value€39.03
Total Cash (Recent Filing)€7.63M
Total Debt (Recent Filing)€8.91M
Price to Earnings (P/E)―
Beta-84.51
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding1,711,808,500
10 Day Avg. Volume4,037
30 Day Avg. Volume2,593
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-1.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageLimited debt reduces interest and refinancing pressure, giving SpectraCure more financial flexibility while it develops its platform. However, this advantage is partly offset by ongoing losses and the need to fund operations through cash reserves or external capital.
Differentiated PDT PlatformCombining minimally invasive light delivery with real-time treatment monitoring could support differentiated clinical performance and adoption if validated. This technology focus may create a defensible position in targeted cancer treatment and support future hospital use.
Recurring Procedure Revenue PotentialA model combining installed systems with treatment consumables could provide recurring revenue as clinical utilization expands. That structure can improve customer lifetime value and revenue visibility over time, although adoption, approvals, reimbursement and pricing remain unproven.
Bears Say
No Meaningful RevenueThe absence of meaningful revenue indicates that SpectraCure has not yet demonstrated commercial adoption or a repeatable operating model. This leaves future performance dependent on clinical progress, regulatory milestones and eventual customer conversion rather than established demand.
Persistent LossesLarge operating and net losses, together with negative gross profit, show that the business remains in a heavy investment phase without evidence of operating leverage. Sustained losses could delay profitability and require continued capital support before the platform scales.
Cash Burn And Funding RiskPersistent negative operating and free cash flow means internal cash generation is insufficient to fund operations. SpectraCure therefore remains reliant on cash reserves or external financing, creating potential dilution and execution risk if funding conditions or investor support weaken.
2OK FAQ
What was SpectraCure AB’s price range in the past 12 months?
SpectraCure AB lowest stock price was <€0.01 and its highest was €0.16 in the past 12 months.
What is SpectraCure AB’s market cap?
SpectraCure AB’s market cap is €5.11M.
When is SpectraCure AB’s upcoming earnings report date?
SpectraCure AB’s upcoming earnings report date is Nov 13, 2026 which is in 77 days.
How were SpectraCure AB’s earnings last quarter?
SpectraCure AB released its earnings results on Aug 21, 2026. The company reported >-€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is SpectraCure AB overvalued?
According to Wall Street analysts SpectraCure AB’s price is currently Overvalued.
Does SpectraCure AB pay dividends?
SpectraCure AB does not currently pay dividends.
What is SpectraCure AB’s EPS estimate?
SpectraCure AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SpectraCure AB have?
SpectraCure AB has 1,711,808,500 shares outstanding.
What happened to SpectraCure AB’s price movement after its last earnings report?
SpectraCure AB reported an EPS of >-€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of SpectraCure AB?
Currently, no hedge funds are holding shares in DE:2OK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SpectraCure AB
SpectraCure AB (publ) specializes in oncology, developing innovative cancer treatments that harness laser light and photodynamic agents. A cornerstone of their research is the IDOSE software, which powers an interstitial photodynamic therapy (PDT) system. This cutting-edge system is currently in Phase II clinical trials, where its efficacy in addressing solid tumors is being evaluated. The Swedish company, established in Lund in 2003, continues to advance its therapeutic solutions.
Technical Analysis
Paxman AB
―
SciBase Holding AB
―
Bactiguard Holding AB
―
BrainCool AB
―
ScandiDos AB
―